Grünenthal has announced the successful extension of its existing EUR535 million term loan bank facilities. This amendment was conducted in the broader context of the company's acquisition of the European rights (excluding Spain and the UK) to the lipid-lowering medication CRESTOR(TM) completed in February 2021.

The term loan maturities are now aligned with Grünenthal's Revolving Credit Facility maturity, which further extends its debt maturity profile. More than 60 percent of Grünenthal's debt facilities now mature in 2024 or later. Grünenthal's capital structure has enabled it to enter into a series of acquisitions and partnerships in recent years. The company has signed transactions with a total value of more than US$ 1.7 billion since 2016. These include the global rights to Qutenza(TM) and the global (excluding Japan) rights to Zomig(TM), as well as the European rights to Nexium(TM) and global (excluding US and Japan) rights to Vimovo(TM), which is the biggest single investment in the company's history.